Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Boston's Rgenta Raises $20 Million for RNA Therapies from China-Heavy Syndicate

publication date: Apr 2, 2020

Rgenta Therapeutics, a Cambridge, Mass. biotech startup, raised $20 million in seed funding from a syndicate that includes China investors. The company is developing small molecule candidates that target RNA regulation and splicing of disease-causing genes in oncology and neurological disorders. The targets are undruggable by traditional approaches, Rgenta says. The funding was co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China, and it also included Hangzhou Kaitai Capital and Legend Star Fund, an offshoot of China's Lenovo Group. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital